A Phase II Study of Dasatinib in Children and Adolescents Newly Diagnosed with Chronic Phase CML or with Philadelphia Chromosome-Positive Leukemias Resistant to or Intolerant of Imatinib

Full Title
A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Dasatinib is an anticancer drug approved for the treatment of adults with chronic myelogenous leukemia (CML) or Philadelphia (Ph) chromosome-positive leukemia and who are not benefiting from or cannot tolerate conventional treatments such as imatinib. In this study, researchers want to evaluate the effectiveness of dasatinib in children and adolescents newly diagnosed with CML OR with Ph-positive leukemias resistant to or intolerant of imatinib.

Dasatinib works by interfering with the signaling pathways cancers need to grow. It is a medicine that is taken by mouth.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must be children or adolescents with chronic phase CML that has not yet been treated, OR have Ph chromosome-positive CML or acute lymphoblastic leukemia and be resistant to or intolerant of imatinib.
  • Patients must be age 18 or younger.
  • Patients must have recovered from the side effects of prior therapies.

For more information about this study and to inquire about eligibility, please contact Dr. Neerav Shukla at 212-639-5158.

Leukemia: Chronic Myelocytic Leukemia
Related Diseases